Approach
Team
News
Portfolio
Apply for funding
en
de
OctreoPharm
Advancing nuclear medicine through innovative theranostic compounds for neuroendocrine tumor management.
Exit: 2015 Trade Sale an IPSEN
invested since
2011
↙ Back to Portfolio
